HMR-59

GA treatments are advancing rapidly, with oral, gene, and cell therapies emerging as contenders to intravitreal injections in preserving vision. Innovation in GA is no longer a luxury-it’s a necessity. Next-gen therapies must deliver more than anatomical slowing; they must give patients functional hope and real-world relief.” — DataM Intelligence AUSTIN, TX, UNITED STATES, June 9, 2025 / EINPresswire.com / -- Geographic Atrophy (GA) , a late-stage and irreversible form of dry age-related macular degeneration (AMD), has long symbolized a dead end in the journey to preserve sight. Characterized by the progressive degeneration of the retinal pigment epithelium, photoreceptors, and surrounding support tissue, GA leads to central vision loss-a critical blow to quality of life for millions of older adults. As the global population ages, GA’s burden grows heavier, with an estimated 5 million people affected worldwide, including over 1 million in the U.S. alone. Yet, for years, treatment options remained virtually nonexistent. Book Your Free CI Consultation Call: https://www.datamintelligence.com/strategic-insights/ci/geographic-atrophy-ga That paradigm is now shifting. A Landscape Defined by Milestone Approvals Until recently, patients and physicians had no pharmacologic recourse. But in the past two years, the U.S. Food and Drug Administration has greenlit two targeted therapies that mark a significant breakthrough: Syfovre (pegcetacoplan) by Apellis Pharmaceuticals and Izervay (avacincaptad pegol) by Astellas Pharma. Both are intravitreal injections that target the complement system, a key contributor to retinal inflammation and cell death in GA. Syfovre inhibits complement component C3, offering broad suppression across the complement cascade. Izervay, in contrast, selectively inhibits C5, aiming for efficacy with a potentially more favorable safety profile. Their approval represents a long-awaited step forward, transforming a previously untreatable condition into a manageable disease-at least in theory. However, enthusiasm is tempered by real-world complexity. Monthly or bimonthly eye injections carry risks-most notably intraocular inflammation, a safety signal associated with Syfovre-and impose a significant treatment burden on elderly patients. Additionally, while these drugs can slow the progression of GA lesions, they do not restore lost vision or significantly improve functional outcomes like reading speed or contrast sensitivity. The Pipeline Awakens: A New Generation of Therapies As of mid-2025, the treatment landscape is in the midst of a competitive and technological renaissance. More than half a dozen late-stage candidates are racing toward the market, aiming to challenge or complement the status quo. Regeneron’s pozelimab, a C5 inhibitor in Phase III trials, is perhaps the most direct competitor. Leveraging Regeneron’s strong retina portfolio, it poses a high threat to existing market leaders. Meanwhile, Annexon’s ANX007, a C1q inhibitor, represents a mechanistically novel approach targeting upstream complement activity with added neuroprotective benefits. But the most disruptive contenders come from outside the intravitreal injection space. Belite Bio’s Tinlarebant, an oral RBP4 inhibitor, offers a daily pill that sidesteps the logistical and emotional challenges of eye injections. Similarly, Gildeuretinol by Alkeus is exploring the vitamin A pathway with oral systemic delivery aimed at reducing retinal stress. Adding further depth to the field are therapies exploring regenerative and long-term solutions. Roche’s OpRegen, a subretinal cell replacement therapy, seeks to regenerate lost retinal pigment epithelium cells. Johnson & Johnson’s gene therapy candidate JNJ-1887 aims for durable complement inhibition via a single intravitreal injection-a potential game-changer if successful. Market Momentum and the Rise of the Target Opportunity Profile (TOP) With multiple late-phase contenders poised for readouts between 2025 and 2027, developers are increasingly judged by their Target Opportunity Profile (TOP)-a multi-dimensional framework assessing not just efficacy and safety, but also delivery method, durability, innovation, and functional benefit. A high-value therapy in this evolving landscape must go beyond anatomical slowing. It must preserve or improve visual function, minimize side effects, and ideally reduce the frequency of administration. Oral drugs like Tinlarebant and Gildeuretinol score high on patient convenience, while gene and cell therapies offer the tantalizing prospect of single-dose, long-lasting solutions. From a payer and provider perspective, differentiation is key. Novel mechanisms of action such as ANX007’s C1q inhibition or AVD-104’s siglec-targeted nanoparticle technology introduce innovation that could address patient subtypes who are non-responsive to existing drugs. Moreover, dosing frequency and route of administration are taking center stage. The real-world success of any emerging GA therapy hinges on its ability to reduce clinic visits and improve compliance among a predominantly elderly population. Sustained-delivery implants, gene therapies, or oral regimens have clear advantages in this context. Competitive Positioning: A Strategic Chessboard While Syfovre and Izervay currently dominate the market, they face increasing competition from therapies designed for ease-of-use and differentiated clinical value. Regeneron’s pozelimab is a direct competitor with strong corporate backing. Belite’s Tinlarebant and Alkeus’s Gildeuretinol address a different market segment entirely-patients wary of intravitreal injections. Annexon’s ANX007 could appeal to early-stage GA patients thanks to its neuroprotective mechanism. Cell-based and gene therapies, though still in earlier stages, present long-term threats with the potential to redefine treatment expectations. However, scalability, delivery challenges, and cost-effectiveness will be critical hurdles to overcome. A Market Poised for Reimagination The GA market, currently valued in the low billions, is set for robust growth through the end of the decade. But more than financial metrics, it is the transformation in patient experience and clinical possibility that will define this new era. To achieve commercial success and physician buy-in, future GA therapies must offer a balance of safety, efficacy, innovation, and convenience. Emerging treatments will only be as strong as the real-world outcomes they can deliver-preserved independence, improved daily function, and hope for those slowly going blind. Download Free CI Sample Report: https://www.datamintelligence.com/strategic-insights/ci/geographic-atrophy-ga Final Word Geographic atrophy is no longer a therapeutic void. With a rapidly advancing pipeline, the market is shifting from a mindset of damage control to one of proactive preservation-and even potential restoration-of vision. As new entrants race toward approval, they must answer a singular question: Can they improve not just the lesion, but the life behind the lens? Read Related CI Reports: 1. Lupus Nephritis | Competitive Intelligence 2. Immune Thrombocytopenia (ITP) |Competitive Intelligence Sai Kiran DataM Intelligence 4market Research LLP +1 877-441-4866 email us here Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Five abstracts to be presented, including new real-world research and data on Janssen's investigational gene therapy JNJ-1887 RARITAN, N.J., Oct. 3, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that five company-sponsored presentations will be featured during the European Society of Retina Specialists (EURETINA) 2023 annual meeting, taking place in Amsterdam, from October 5-8. The Company's presentations will include safety analysis data from two Phase 1 trials of the investigational gene therapy JNJ-81201887 (JNJ-1887): one trial in patients with geographic atrophy (GA), an advanced stage and severe form of age-related macular degeneration (AMD), and one trial in wet AMD (Abstracts #CA231214 and #CA231118).1,2 In addition, new research highlighting descriptive analyses of real-world GA trial populations, patients' perspectives on the symptoms and impact of X-linked retinitis pigmentosa (XLRP) and comorbidities among inherited retinal dystrophy patients will also be shared (Abstracts #CA231637, #CA231346 and #CA23429).3,4,5 Continue Reading Dare to Envision Courageous Science Normal Anatomy of the Retina Experience the full interactive Multichannel News Release here: "These data at EURETINA 2023 help bring us one step closer to a new era of innovation in retina," said James List, M.D., Ph.D., Global Therapeutic Area Head, whose team oversees a portfolio of programs including Retina at Janssen Research & Development, LLC. "We're committed to building on this momentum – and doing so with boldness and urgency – as we advance our mission to restore and preserve vision for those living with retinal diseases." GA is an advanced form of AMD.6 It affects more than five million individuals globally and is a leading cause of blindness in people over 65 years of age.5 It has a devastating impact on these patients and their quality of life, including their ability to read, drive and perform other day-to-day activities.5 XLRP is a rare inherited condition estimated to impact one in 40,000 people globally.7,8 People with XLRP have progressive vision loss, starting in childhood with night blindness.9 Over time, they lose their peripheral vision, and by approximately age 40, many are legally blind.8 Currently, there are no approved treatments for XLRP.8 A complete listing of the Company's abstracts being featured at the EURETINA Annual Meeting is provided below. Abstracts can also be found on the EURETINA website. Janssen will also have an interactive Retina Medical Affairs exhibit booth (location #12.115) at the EURETINA annual meeting. For more information about Janssen Retina's research and portfolio, please visit . About JNJ-1887 JNJ-81201887 (JNJ-1887), formerly referred to as AAVCAGsCD59, is an investigational one-time gene augmentation therapy for the treatment of people with geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). JNJ-1887 is designed to increase local expression of a soluble form of CD59 (sCD59) to possibly reduce MAC formation and protect retinal cells, thus potentially slowing and preventing disease progression. The Phase 2b PARASOL clinical trial (NCT05811351) is actively enrolling patients to study JNJ-1887 for the treatment of adults 60 or older with advanced dry AMD with GA. JNJ-1887 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) and Advanced Therapy Medicinal Product (ATMP) designation by the European Medicines Agency (EMA). About botaretigene sparoparvovec (bota-vec) Botaretigene sparoparvovec (bota-vec) is being investigated in collaboration with MeiraGTx Holdings plc for the treatment of patients with X-linked retinitis pigmentosa (XLRP) caused by disease-causing variants in the eye-specific form of the RPGR gene. Through a one-time administration, bota-vec is designed to deliver functional copies of the RPGR gene that may counteract the loss of retinal cells with the goal of preserving and potentially restoring vision for those living with XLRP. The Phase 3 LUMEOS clinical trial (NCT04671433) has surpassed enrollment and is evaluating participants to study bota-vec for the treatment of patients living with XLRP with disease-causing variants in the RPGR gene. Bota-vec has been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration (FDA) and PRIority MEdicines (PRIME), Advanced Therapy Medicinal Product (ATMP) and Orphan designations by the European Medicines Agency (EMA). About the Janssen and MeiraGTx Strategic Collaboration In January 2019, Janssen Research & Development, LLC entered into a worldwide collaboration and license agreement with MeiraGTx Holdings plc, a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical-stage inherited retinal disease portfolio. Botaretigene sparoparvovec (bota-vec) is being developed as part of a collaboration and license agreement. In addition to forming a research collaboration to explore new targets for other inherited retinal diseases, Janssen is working with MeiraGTx to build core capabilities in viral vector design, optimization and manufacturing. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at . Follow us at @JNJInnovMed and @JanssenUS. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding botaretigene sparoparvovec and JNJ-81201887. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , or on request from Johnson & Johnson. Neither Janssen Research & Development, LLC nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. ________________________________ 1 Holz F et al. Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy (GA) Due to Age-related Macular Degeneration (AMD). Abstract #CA231214. European Society of Retina Specialists 2023 Annual Meeting. 2 Fischer, DM et al. Pooled Safety Analysis of a Single Intravitreal Injection of JNJ-1887 (Gene Therapy, AAVCAGsCD59) in Patients With Age-Related Macular Degeneration (AMD). Abstract #CA231118. European Society of Retina Specialists 2023 Annual Meeting. 3 Besirli, C et al. Concept elicitation interviews to obtain patients' perspectives on the symptoms and impacts of X-linked retinitis pigmentosa. Abstract #CA231346. European Society of Retina Specialists 2023 Annual Meeting. 4 Wennberg, A et al. Comorbidities Among Inherited Retinal Dystrophy Patients in Sweden: A National Patient Register Study. Abstract #CA23429. European Society of Retina Specialists 2023 Annual Meeting. 5 Gale, SL et al. Descriptive analyses of a real-world cohort of patients with geographic atrophy secondary to age-related macular degeneration. Abstract #CA231637. European Society of Retina Specialists 2023 Annual Meeting. 6 Cohen, MN et al. Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy (GA) Due to Age-related Macular Degeneration (AMD). Abstract #30071749. Presented at the 2022 American Academy of Ophthalmology Annual Meeting 7 Boughman JA, Conneally PM, Nance WE. Population genetic studies of retinitis pigmentosa. Am J Hum Genet. 1980;32(2):223–235. 8 Fishman GA. Retinitis pigmentosa. Genetic percentages. Arch Ophthalmol. 1978;96(5):822–826. 9 Wang DY, Chan WM, Tam PO, et al. Gene mutations in retinitis pigmentosa and their clinical implications. Clin Chim Acta. 2005;351(1-2):5-16. Me d i a Inquiries: Jennifer Silvent Mobile +1 973-479-9845 Rachael Jarnagin Mobile +1 415-705-9023 Investor Relations: Raychel Kruper Office +1 732-524-6164 [email protected] Click to Access Audio SOURCE Johnson & Johnson Innovative Medicine